The role of α-zearalanol in reversing bone loss induced by ovarian hormone deficiency in rats

Abstract

To assess the ability of α-zearalanol (α-ZAL) to prevent bone loss in an ovariectomized (OVX) rat model of osteoporosis, α-ZAL was administered intragastrically to rats. After 35days, the total body bone mineral density (BMD) was assessed in all rats. All sections were processed for immunohistochemistry and hematoxylin and eosin staining. One-way ANOVA and an LSD multiple-range test were used to determine the significant differences between groups. BMD was lower in the OVX and OVX+α-ZAL high-dose (OVX+High) groups compared to the sham-operated (Sham), OVX+17β-ethinylestradiol (OVX+E(2)), OVX+α-ZAL medium-dose (OVX+Medium) and OVX+α-ZAL low-dose (OVX+Low) groups (P<0.05). Clear bone trabeculae arrangements were observed in the OVX+E(2,) OVX+Medium and OVX+Low groups. The expressions of bone morphogenetic proteins and basic fibroblast growth factor were up-regulated in the OVX+E(2), OVX+Medium and OVX+Low groups compared to the OVX and OVX+High groups (P<0.05). The OVX+E(2), OVX+Medium and OVX+Low groups showed lower levels of bone Gla protein, bone alkaline phosphatase, tartrate-resistant acid phosphatase and tumor necrosis factor α expressions than the OVX and OVX+High groups (P<0.05). The administration of α-ZAL to ovariectomized rats reverses bone loss and prevents osteoporosis.